AI tool successfully predicts outcomes of immunotherapy in lung cancer
Artificial intelligence (AI) tools can help physicians predict treatment and survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with immunotherapy, according to a new study published in Nature Medicine. The study reported findings from the I3LUNG project, a large international trial aimed at improving the treatment of metastatic NSCLC by developing AI-based…
A new study published in Nature Medicine has found that artificial intelligence tools can accurately predict treatment and survival outcomes for advanced non-small cell lung cancer (NSCLC) patients undergoing immunotherapy. The research, part of the I3LUNG project, involved 2,396 patients across six countries and utilized a multimodal AI model that integrated clinical, blood, imaging, pathology, and genomic data to achieve an impressive AUC score of 0.88.
This performance surpassed standard clinical biomarkers, indicating that AI could help physicians better tailor treatments to individual patients, avoiding unnecessary toxicity and cost. When physicians collaborated with the AI tool, its sensitivity for identifying treatment responders increased from 0.72 to 0.87, and interphysician agreement improved, suggesting that AI could enhance clinical reasoning across different levels of expertise.
The study concludes that an AI-assisted decision support tool could provide expert-level guidance at the point of care for community physicians and serve as a global platform for precision immunotherapy in the future.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
